Biomarkers in the management of scleroderma: an update
- PMID: 21046295
- DOI: 10.1007/s11926-010-0140-z
Biomarkers in the management of scleroderma: an update
Abstract
Scleroderma, or systemic sclerosis, is a clinically heterogeneous disease characterized by fibroproliferative vasculopathy, tissue fibrosis affecting the skin and internal organs, and autoimmune activation. Many biomarker candidates have been identified in the past two decades; however, fully validated measures are still lacking with regard to aiding in the early diagnosis and reflecting the disease activity, severity, prognosis, and response to therapy. An ideal biomarker should be highly sensitive and specific, reflecting the current status of disease; should be related to the disease activity and/or severity in accordance with the clinical evolution; should anticipate clinical changes before they occur; and should add independent information about the risk or prognosis that is reproducible and feasible. This review focuses on the most recent and innovative approaches to identify biomarkers, such as extensive gene expression analysis and proteomics, and on markers and surrogate outcome measures closer to clinical practice, and attempts to evaluate them through the OMERACT (Outcome Measures in Rheumatology Clinical Trials) filter.
Similar articles
-
N-TproBNP as biomarker in systemic sclerosis.Clin Rev Allergy Immunol. 2012 Dec;43(3):292-301. doi: 10.1007/s12016-012-8312-4. Clin Rev Allergy Immunol. 2012. PMID: 22669751 Review.
-
An update on biomarker discovery and use in systemic sclerosis.Expert Rev Mol Diagn. 2017 Sep;17(9):823-833. doi: 10.1080/14737159.2017.1356722. Epub 2017 Jul 25. Expert Rev Mol Diagn. 2017. PMID: 28730919 Review.
-
Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.Semin Immunopathol. 2015 Sep;37(5):475-87. doi: 10.1007/s00281-015-0506-4. Epub 2015 Jul 14. Semin Immunopathol. 2015. PMID: 26168983 Free PMC article. Review.
-
Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.Curr Rheumatol Rep. 2016 Mar;18(3):17. doi: 10.1007/s11926-016-0565-0. Curr Rheumatol Rep. 2016. PMID: 26970773 Review.
-
MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma.Exp Mol Med. 2013 Sep 20;45(9):e41. doi: 10.1038/emm.2013.71. Exp Mol Med. 2013. PMID: 24052166 Free PMC article. Review.
Cited by
-
Biomarkers as an opportunity to stratify for outcome in systemic sclerosis.Eur J Rheumatol. 2020 Oct;7(Suppl 3):S193-S202. doi: 10.5152/eurjrheum.2020.19065. Epub 2020 Jul 20. Eur J Rheumatol. 2020. PMID: 32697933 Free PMC article. Review.
-
Personalized medicine in systemic sclerosis: facts and promises.Curr Rheumatol Rep. 2014 Jun;16(6):425. doi: 10.1007/s11926-014-0425-8. Curr Rheumatol Rep. 2014. PMID: 24752884 Review.
-
An Ultrasound Surface Wave Technique for Assessing Skin and Lung Diseases.Ultrasound Med Biol. 2018 Feb;44(2):321-331. doi: 10.1016/j.ultrasmedbio.2017.10.010. Epub 2017 Dec 1. Ultrasound Med Biol. 2018. PMID: 29195756 Free PMC article.
-
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.Int J Rheumatol. 2011;2011:842181. doi: 10.1155/2011/842181. Epub 2011 Oct 13. Int J Rheumatol. 2011. PMID: 22013450 Free PMC article.
-
Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling.J Immunol. 2012 Sep 1;189(5):2635-44. doi: 10.4049/jimmunol.1201115. Epub 2012 Jul 23. J Immunol. 2012. PMID: 22826322 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous